References
- Otberg N, Kang H, Alzolibani AA, et al. Folliculitis decalvans. Dermatol Ther. 2008;21:238–44
- Goo B, Chung HJ, Chung WG, et al. Intramuscular immunoglobulin for recalcitrant suppurative diseases of the skin: a retrospective review of 63 cases. Br J Dermatol. 2007;157:563–8
- Quinquaud E. Folliculite épilante et destructive des regions values. Bull Mem Soc Hop Paris. 1888;5:395–8
- Powell JJ, Dawber RPR, Gatter K. Folliculitis decalvans including tufted folliculitis: clinical, histological and therapeutic findings. Br J Dermatol. 1999;140:328–33
- Chiarini C, Torchia D, Bianchi B, et al. Immunopathogenesis of folliculitis decalvans. Clues in early lesions. Am J Clin Pathol. 2008;130:526–34
- Laxer RM, Schaffer FM, Myones BL, et al. Lymphocyte abnormalities and complement activation in Kawasaki disease. Proc Clin Biol Res. 1987;250:175–84
- Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602–7
- Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory disease. N Engl J Med. 2012;367:2015–25
- Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Safety. 1993;9:254–62